A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study
References (37)
- et al.
Antimalarials in rheumatology: efficacy and safety
- et al.
The course of rheumatoid arthritis
Balliére's Clin Rheumatal
(1992) - et al.
The long-term outcome and justification for early treatment
Ballière's Clinical Rheumatal
(1992) - et al.
Measurement of outcome in rheumatoid arthritis
Baffière's Clinical Rheumatol
(1992) The use of Amsler grids in early chloroquine retinopathy
Ophtnalmology
(1984)- et al.
Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial
Am J Med
(1986) - et al.
Long-term outcome of treating rheumatoid arthritis: results after 20 years
Lancet
(1987) - et al.
Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the USA-USSR double-blind placebo-controlled trial
NEJM
(1986) - et al.
The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses
Arthritis Rheum
(1990) - et al.
Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials
Arthritis Rheum
(1992)
The clinical and health status of patients with recent onset rheumatoid arthritis
Arthritis Rheum
Should disease modifying agents be used in mild rheumatoid arthritis
Br J Rheumatol
Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole
J Rheumatol
Termination of slow-acting anti-rheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts
J Rheumatol
Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis
J Rheumatal
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
Arthritis Rheum
Therapeutic criteria in rheumatoid arthritis
JAMA
An experiment in reducing interobserver variability of the examination for joint tenderness
J Rheumatol
Cited by (160)
Hyperlipidemia and rheumatoid arthritis
2022, Cholesterol: From Chemistry and Biophysics to the ClinicThe neurology of lupus
2021, Journal of the Neurological SciencesCitation Excerpt :Two large, prospective, observational cohort studies of SLE [66,69] have reported a lower risk of seizures in patients with SLE taking antimalarial drugs, even after adjusting for potential confounding variables. The precise mechanism responsible for this beneficial effect is not clear but it may result from a combination of the known anti-inflammatory [70,71] and antithrombotic [72] properties of antimalarial drugs. These rare manifestations of SLE occur in 0.7–3% of patients.
Nervous system
2021, Lahita’s Systemic Lupus ErythematosusCharacterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review
2020, Journal of the American Academy of DermatologyHydroxychloroquine safety: A meta-analysis of randomized controlled trials
2020, Travel Medicine and Infectious DiseaseCitation Excerpt :Eight RCTs were double-blind [11–18], and one was single-blind [10]. Only three RCTs were funded by drug companies [11,12,18]. Studies were conducted on four different continents and included patients with a variety of indications.
Factors contributing to disability in rheumatoid arthritis patients: An Egyptian multicenter study
2020, Reumatologia Clinica
- *
The HERA Study Group includes; Principal Investigators and Coordinating Center: John M. Esdaile, MD, MPH, Samy Suissa, PhD, Jeffrey B. Shiroky, MD, Donna Lamping, PhD, Montreal; Project Director: Eva Tsakonas, MSc, Montreal; Consultant Ophthalmologist: Duncan Anderson, MD, Montreal; Consultant Pharmacokineticist: Fakheredin Jamali, PhD, Edmonton; External Monitoring Committee: Matthew H. Liang, MD, MPH, (Chairman), Boston; Simon Carette, MD, Quebec City; Center Investigators: Alfred Cividino, MD, Hamilton; Avril Fitzgerald, MD, Edmonton; Abdelmajid M'Seffar, MD, Montreal; Mary-Ann Fitzcharles, MD, Montreal; John M. Esdaile, MD, MPH, Montreal; Claire Bombardier, MD, Toronto; Carter Thorne, MD, Newmarket; Center Coordinators: Marylin Bell, Lisa Ros, RN, Hamilton; Joyce Lakeman, RN, Edmonton; Dina Perron, Lidia Sunac-Ferguson, RN, Lise Robidoux, RN, Montreal; Vicki Lapp, RN, Toronto and Newmarket; Center Outcome Evaluators: Mary J. Bell, MD, Hamilton; Stephen Aaron, MD, Edmonton; Michel Zummer, MD, Montreal; Michael Starr, MD, Montreal; Kathy Jarka, PhT, Montreal; Deborah Weber, RN, and Da Wen Hu, MD, Toronto and Newmarket; Center Ophthalmologists: Mark Gans, MD, Montreal; Lawrence E. Kobetz, MD, Hamilton; David Climenhaga, MD, Edmonton; Michael Easterbrook, MD, Toronto; Leslie Landecker, MD, Newmarket.